HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) is excited to announce that the Late-Breaking Abstract (LBA) from the registrational Phase III clinical study (AK112-306/HARMONi-6 study) of ivonescimab, a globally first-in-class bispeci... [8636 chars].. PR
